TABLE 1.
Patient demographic and clinical characteristics.
| Characteristic a | Patients with ES‐SCLC (N = 1239) |
|---|---|
| Age, years, mean (SD) [median] | 66.9 (9.3) [68.0] |
| Age group, n (%) | |
| <65 years | 462 (37.3) |
| ≥65 years | 777 (62.7) |
| Male, n (%) | 616 (49.7) |
| Race, n (%) | |
| White | 719 (58.0) |
| Black | 27 (2.2) |
| Asian | 1 (0.1) |
| Other | 441 (35.6) |
| Unknown | 51 (4.1) |
| ECOG PS b , n (%) | |
| 0 | 299 (24.1) |
| 1 | 500 (40.4) |
| 2 | 170 (13.7) |
| ≥3 | 65 (5.2) |
| Unknown | 205 (16.5) |
| Continuous non‐cancer‐related CCI, mean (SD) | 0.2 (0.5) |
| Categorical non‐cancer‐related CCI, n (%) | |
| 0 | 1116 (90.1) |
| 1 | 77 (6.2) |
| ≥2 | 46 (3.7) |
| Non‐cancer‐related CCI comorbidities c , n (%) | |
| Chronic pulmonary disease | 68 (5.5) |
| Mild liver disease | 28 (2.3) |
| Renal disease | 2.2 (2.2) |
| Myelosuppressive events before index d , n (%) | |
| Grade ≥ 3 neutropenia | 17 (3.5) |
| Grade ≥ 3 anemia | 8 (1.6) |
| Grade ≥ 3 thrombocytopenia | 6 (1.2) |
| Grade ≥ 3 lymphopenia | 12 (2.5) |
| Grade ≥ 3 leukopenia | 14 (2.9) |
| Index LOT, n (%) | |
| 1 | 1165 (94.0) |
| 2 | 71 (5.7) |
| ≥3 | 3 (0.2) |
| Follow‐up from index date, days, mean (SD) [median] | 10.4 (11.3) [7.3] |
Abbreviations: CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; IO, immuno‐oncology treatment; LOT, line of therapy; SD, standard deviation.
Measured any time prior to the index treatment date with the exception of ECOG, myelosuppressive events, and follow‐up time.
Measured within 60 days before or 14 days after the index treatment date. Levels defined as 0 = Fully active, able to carry on all pre‐disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; 2 = Ambulatory and capable of all self‐care but unable to carry out any work activities; up and about more than 50% of waking hours; 3 = Capable of only limited self‐care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled, cannot carry on any self‐care, totally confined to bed or chair; 5 = Dead.
Limited to comorbidities with prevalence >1%.
Measured 30 days before the index treatment date.